Search results with tag "Saxenda"
PRODUCT MONOGRAPH
www.novonordisk.caSAXENDA® (liraglutide) Page 1 of 47. PRODUCT MONOGRAPH. SAXENDA®. liraglutide . 6 mg/mL . Solution for Injection in a pre-filled pen . Human Glucagon Like Peptide-1 (GLP-1) Weight Management
MEDICATION GUIDE What is the most important information I ...
www.novo-pi.comMEDICATION GUIDE Saxenda (sax-end-ah) (liraglutide) injection solution for subcutaneous use What is the most important information I should know about Saxenda?
An invitation to participate in the Saxenda Pharmacy ...
www.pharmacyalliance.com.au‒The TGA has recently approved Saxenda® for use in suitable patients Novo Nordisk is recognised as the leader in diabetes care with over 90 years experience Novo Nordisk has an ambition to become a global leader in the management
HIGHLIGHTS OF PRESCRIBING INFORMATION - novo-pi.com
www.novo-pi.comSaxenda ® liraglutide) njection 2 FULL PRESCRIBING INFORMATION WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment- duration-dependent thyroid C-cell tumors at clinically relevant exposures in both genders of
HIGHLIGHTS OF PRESCRIBING INFORMATION - …
www.novo-pi.comSaxenda ® liraglutide) njection 2 FULL PRESCRIBING INFORMATION WARNING: RISK OF THYROID C-CELL TUMORS • Liraglutide causes dose-dependent and treatment- duration-dependent thyroid C-cell tumors at
Saxenda liraglutida - Novo Nordisk Brasil
www.novonordisk.com.brSaxenda – Bula Paciente (2016, CCDS v 5.0, 22/Sep/2016 (v.3)) 1 of 13 Saxenda™ liraglutida IDENTIFICAÇÃO DO MEDICAMENTO Saxenda™ liraglutida APRESENTAÇÕES
Saxenda - Novo Nordisk Australia
www.novonordisk.com.auSaxenda® Page 3 of 11 Saxenda cmi1 Week 4 2.4mg once a day Week 5 onwards 3.0mg once a day Once you reach the recommended dose of 3.0mg in Week 5 of treatment, keep using this dose until